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Introduction
Systemic sclerosis (scleroderma, SSc) is an auto-
immune connective tissue disease characterized 
by skin and internal organ fibrosis, coupled with 
widespread vascular pathology [Korn, 2001]. 
Skeletal muscle involvement in SSc was first con-
sidered in 1876, as a minor component of the dis-
ease associated with disuse [Medsger et al. 1968]. 
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Abstract
Objectives: The objective of this study was to identify specific histopathological features of 
skeletal muscle involvement in systemic sclerosis (SSc) patients.
Methods: A total of 35 out of 112 SSc-patients (32%, including 81% female and 68% diffuse 
scleroderma) presenting clinical, biological and electromyographic (EMG) features of 
muscle weakness, were included. Patients underwent vastus lateralis biopsy, assessed for 
individual pathologic features including fibrosis [type I collagen (Coll-I), transforming growth 
factor β (TGF-β)], microangiopathy [cluster of differentiation 31 (CD31), pro-angiogenic 
vascular endothelial growth factor A (VEGF-A), anti-angiogenic VEGF-A165b], immune/ 
inflammatory response [CD4, CD8, CD20, human leucocyte antigens ABC (HLA-ABC)], and 
membranolytic attack complex (MAC). SSc biopsies were compared with biopsies of (n = 35) 
idiopathic inflammatory myopathies (IIMs) and to (n = 35) noninflammatory myopathies (NIMs). 
Ultrastructural abnormalities of SSc myopathy were also analyzed by transmission electron 
microscopy (TEM).
Results: Fibrosis in SSc myopathy (81%) is higher compared with IIM (32%, p < 0.05) and with 
NIM (18%, p < 0.05). Vascular involvement is dominant in SSc muscle (92%), and in IIM (78%) 
compared with NIM (21%, p < 0.05). In particular, CD31 shows loss of endomysial vessels in 
SSc myopathy compared with IIM (p < 0.05) and with NIM (p < 0.01). VEGF-A is downregulated 
in SSc myopathy compared with IIM (p < 0.05) and NIM (p < 0.05). Conversely, VEGF-A165b is 
upregulated in SSc myopathy. The SSc immune/inflammatory response suggested humoral 
process with majority (85%) HLA-ABC fibral neoexpression and complement deposits on 
endomysial capillaries MAC, compared with IIM (p < 0.05), characterized by CD4+/CD8+/B-
cell infiltrate, and NIM (p < 0.05). TEM analysis showed SSc vascular alterations consisting of 
thickening and lamination of basement membrane and endothelial cell ‘swelling’ coupled to 
endomysial/perimysial fibrosis.
Conclusions: Fibrosis, microangiopathy and humoral immunity are predominant in SSc 
myopathy, even if it is difficult to identify specific histopathological hallmarks of muscle 
involvement in SSc, since they could be present also in other (IIM/NIM) myopathies.
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Nowadays, SSc skeletal muscle involvement turns 
out to be a common feature, with prevalence from 
14% to 79% [Paik et  al. 2014]. This variable 
prevalence results from the heterogeneous criteria 
used to define muscle involvement in SSc, includ-
ing clinical, biological, electromyographic (EMG) 
and histological features of muscle weakness 
[Olsen et  al. 1996]. In fact, SSc myopathy can 
occur for different reasons, such as result of non-
autoimmune etiologies: malnutrition, disuse, or 
other neuromuscular disorders [Clements et  al. 
1978]. Another important issue related to defin-
ing specific criteria for recognizing ‘SSc myopa-
thy’ as such an entity, is the exclusion (or not) of 
SSc overlap syndromes, since inflammatory myo-
pathies such as polymyositis (PM) or dermatomy-
ositis (DM) are a common feature in these 
syndromes [Pope, 2002]. Despite the absence of 
definite criteria for the diagnosis of ‘SSc myopa-
thy’, researchers agree on the fact that SSc-muscle 
involvement is a negative prognostic feature 
impacting survival, and has also been associated 
with cardiopulmonary complications and even 
sudden cardiac death [Follansbee et al. 1993]. For 
these reasons, in the present study we tried to 
identify histopathological hallmarks of ‘SSc myo-
pathy’ that could be unique for the disease itself 
and not common to other idiopathic inflammatory 
myopathies (IIM) or to other noninflammatory 
myopathies (NIM).
Methods
Patients and diagnostic procedures
We admitted 112 SSc patients in our institution 
from 2010 to 2015. Patients who had been diag-
nosed according to the 2013 American College of 
Rheumatology and European League Against 
Rheumatism (ACR/EULAR) diagnostic criteria 
for SSc [Van Den Hoogen, 2013], were enrolled. 
In total, 35 out of the 112 (32%, including 81% 
female and 68% diffuse scleroderma) who pre-
sented clinical, biological and EMG features of 
muscle involvement, were enrolled. Table 1 
shows the main clinical and biological features of 
enrolled patients. Patients underwent biopsy of 
the vastus lateralis muscle. Specimens were fro-
zen in liquid nitrogen-cooled isopentane and 
stored at −80°C until use. Cryostat sections were 
submitted to diagnostic routine histological and 
histochemical stains. SSc muscle biopsies were 
compared with (n = 35, site-matched) biopsies of 
patients with IIM, diagnosed following current 
clinicopathological criteria [Dalakas, 2010] [(n = 
15 PM; n = 10 DM; n = 10 inclusion body myosi-
tis (IBM)], and to (n = 35, site-matched) biopsies 
of patients with NIM (n = 21 (A) metabolic myo-
pathies, n = 14 (B) congenital myopathies): (A) 
n = 5 aspecific myopathic changes at biopsy; n = 
4 statin associated rhabdomyolysis; n = 4 mito-
chondrial myopathy; n = 3 muscle glycogenosis; 
n = 5 steroid myopathy. (B) n = 2 calpainopathy; 
n = 3 mild dystrophinopathy; n = 2 myotonic dys-
trophy type 1; n = 2 myotonic dystrophy type 2; 
n = 2 facioscapulohumeral dystrophy; n = 3 oligo-
symptomatic familial hyperckemia). All subjects 
signed an informed consent, with allowance for 
scientific utilization of muscle samples for 
research purposes, in accordance to the principles 
of the 1975 Declaration of Helsinki (revised Hong 
Kong 1989) and the entire study protocol was 
approved by the institutional review board of the 
Ethics Committee of the University of Siena.
Histology and histoenzymatic stains
Cryostat 10 µm thick sections were submitted 
to routine hematoxylin–eosin and modified 
Gomori trichrome for morphological evaluation. 
Histoenzymatic stains for nicotinamide adenine 
dinucleotide (NADH) tetrazolium reductase, 
succinic dehydrogenase, cytochrome c oxidase, 
Periodic Acid Schiff (PAS) were also carried out.
Immunohistochemistry
Immunohistology for diagnostic routine analysis 
[CD4, CD8, CD20, human leucocyte antigens 
ABC (HLA-ABC), membranolytic attack com-
plex (MAC)] (Dako, Glostrup, Denmark) was 
carried out on 7 µm thick cryostat sections on 
silane-coated slides (StarFrost; Knittel Gläser, 
Braunschweig, Germany). Vascular involvement 
was assessed by endothelial marker [cluster of 
differentiation 31 (CD31)] (Dako), pro-angio-
genic vascular endothelial growth factor A 
(VEGF-A) (abcam, Cambridge, UK) and anti-
angiogenic VEGF-A165b (abcam). Muscle fibro-
sis was assessed by the analysis of type I collagen 
(Coll-I) (abcam) and transforming growth factor 
β (TGF-β) (abcam). All the reactions were per-
formed by immunoperoxidase technique, by 
horseradish peroxidase (HRP)-labeled polymer 
(Dako), and 3,3’-diaminobenzidine (Sigma-
Aldrich, Milan, Italy) for visualization. Negative 
controls were performed by the omission of the 
primary antibody.
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Transmission electron microscopy analysis
Ultrastructural analysis of SSc muscle specimens 
was performed routinely after fixation in 2.5% 
glutaraldehyde for 3 h at 4°C, post fixation in 1% 
osmium tetroxide, and embedding in araldite. 
Ultrathin sections were stained with uranyl ace-
tate and lead citrate and were observed at Philips 
EM-10 electron microscope (Huntsville, Alabama, 
USA).
Quantitative analysis on immunohistochemical 
slides
Morphometry was carried out by a Zeiss AxioPlan2 
microscope equipped with AxioVision 4.6 soft-
ware (Carl Zeiss Vision GmbH, Hallbergmoos, 
Germany). Microangiopathy (CD31+ endomysial 
vessels, VEGF-A and VEGF-A165b), inflammation 
(deposits of CD4, CD8, CD20 reactive cells), 
major histocompatibility complex (MHC)-I com-
plex fibral neoexpression HLA-ABC, complement 
deposition MAC and fibrosis (Coll-I, TGF-β) 
were evaluated as histopathological parameters 
of muscle involvement. The density of CD31+ 
endomysial vessels was expressed as a capillary to 
fiber ratio of muscle area, by counting vessels on 
the whole sections immunostained for CD31. 
VEGF analysis consisted of VEGF-A165b/VEGF-A 
ratio of consecutive sections. Inflammatory (CD20, 
CD4, CD8), fibrotic (Coll-I, TGF-β) and comple-
ment deposition MAC scores were assessed on 
three randomly selected fields at 100× magnifica-
tion by automatized colorimetric pixel evaluation, 
detecting the peroxidase reaction product. Each 
score was expressed as the marker+ percentage of 
the total area.
Statistical analysis
Data were evaluated by GraphPad Prism 6® soft-
ware for Windows. Analysis of variance (ANOVA) 
was performed by Kruskal–Wallis test for multiple 
groups. Significance was set at p < 0.05. Data are 
expressed as means ± standard deviations (SD).
Results
Histopathology
General myopathic changes, such as increased 
variability of fiber diameter, scattered atrophic 
fibers and occurrence of internalized nuclei were 
Table 1. Clinical and biological features of enrolled patients.
SSc patients lSSc dSSc
Number of subjects (35) 11 (32%) 24 (68%)
Female sex, N (%) 7 (63%) 21 (87%)
Disease duration years (1st non-
Raynaud’s)
6.4 ± 4.8 7.9 ± 5.6
At the time of muscle biopsy 
(years)
4.5 ± 3.7 4.9 ± 3.7
ANA titer ⩾ 1:160 11 (100%) 24 (100%)
Anti-CENP-B 11 (100%) 0 (0%)
Anti-Scl-70 0 (0%) 24 (100%)
Anti-PM-Scl/Anti-Jo-1 0 (0%) 0 (0%)
Increased CK (>200 mcg/l) 5 (45%) 15 (62%)
Increased LDH (>190 u/l) 4 (36%) 15 (62%)
Increased aldolase (>7.5 u/l) 3 (27%) 9 (37%)
Increased myoglobin (>85 ng/ml)





EMG myopathic motor units 11 (100%) 24 (100%)
lSSc, limited systemic sclerosis; dSSc, diffuse systemic sclerosis; ANA, Anti-nuclear antibodies; CENP-B, Centromere 
Protein B; Scl-70, DNA Topoisomerase I; PM-Scl, exosome; Jo-1, histidyl tRNA synthetase; CK, Creatinine kinase; LDH, 
Lactate dehydrogenase; BMC, British Medical Council; EMG, Electromyography.
Pharmacological treatment: SSc patients enrolled in the study were in treatment with Iloprost (11 lSSc and 24 dSSc) for 
secondary Raynaud’s phenomenon, with dual endothelin-1 receptor antagonist Macitentan (4 lSSc and 16 dSSc) for pul-
monary arterial hypertension (PAH), with dual endothelin-1 receptor antagonist Bosentan (2 lSSc and 4 dSSc) for digital 
ulcers, with prokinetic and proton pump inhibitor agents (1 lSSc and 2 dSSc). It is important to underline that all the SSc 
patients enrolled in the study stopped treatments with low dose corticosteroids (<4–8 mg/die) and with immunosuppres-
sive drugs at least three months before muscle biopsy.
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detected. Multifocal endomysial fibrosis and scat-
tered dilated endomysial capillaries were also 
observed. Necrosis/regeneration was not promi-
nent, with occasional single fiber necrosis in a 
minority of subjects.
Immunohistology and quantitative analysis
Immunohistology for diagnostic routine analysis 
(CD4, CD8, CD20, Figure 1; HLA-ABC, MAC, 
Figure 2) were reported with the relative quanti-
tative analysis. The inflammatory cells result was 
present only in IIM group. Limited or no reactiv-
ity was recorded in NIM (p < 0.001) and SSc (p 
< 0.001) groups, while the sarcolemmal/cyto-
plasmic stain of HLA-ABC and MAC deposition 
on endomysial capillaries is statistically higher in 
SSc myopathy (p < 0.01; p < 0.05) and IIM (p < 
0.01; p < 0.01) groups compared with the NIM 
group. Moreover, HLA-ABC and MAC stainings 
in the SSc myopathy group seem to be compara-
ble to those of IIM group. In Figure 3, vascular 
involvement, represented by VEGF-A, VEGF-
A165b, CD31 and fibrotic component (represented 
by Coll-I and TGF-β) are reported. The VEGF-
A165b:VEGF-A ratio is statistically higher in SSc 
myopathy (p < 0.01) and IIM (p < 0.05) groups 
compared with the NIM group. The density 
of CD31+ endomysial vessels is statistically 
decreased in the SSc myopathy group compared 
with the IIM (p < 0.05) and NIM (p < 0.01) 
groups. In addition, Coll-I and TGF-β reveal 
strong expression in activated endomysial and 
perimysial myofibroblasts of the SSc myopathy 
group, and also in the fibroblasts and in some 
inflammatory cells surrounding the necrotic fib-
ers in the IIM group. Faint Coll-I and TGF-β 
immunoreactivity is recorded in the resident 
endomysial and perimysial fibroblasts of the NIM 
group. Quantitative analysis shows that Coll-I 
and TGF-β are statistically higher in the SSc-
myopathy group compared with the IIM (p < 
0.05; p < 0.01) and NIM (p < 0.01; p < 0.01) 
groups.
Figure 1. Representative images of immunohistological distribution (top) of CD20, CD4, CD8 on consecutive 
sections. Bars are set at 100 µm. Quantitative analysis (bottom) reveals that inflammatory cells are 
predominant in IIM group compared with NIM (***p < 0.001, Kruskal–Wallis) and SSc (***p < 0.001, Kruskal–
Wallis) groups.
IIM, idiopathic inflammatory myopathies; NIM, noninflammatory myopathies; SSc, systemic sclerosis.
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TEM analysis
Figure 4 shows a transmission-electron-micros-
copy (TEM) analysis of SSc muscle biopsies. 
Thickening and lamination of the basement 
membrane (middle), coupled to endothelial cell 
‘swelling’ (left) are the main hallmark of 
SSc microangiopathy. Moreover, considerable 
endomysial fibrosis (right) with a large deposition 
of collagen is also observed.
Discussion
The most important problem when analyzing the 
literature of SSc-related muscle involvement is 
the total absence of specific criteria for the diag-
nosis of such an entity [Ranque et al. 2007]. This 
is because clinical, biological, EMG and histo-
pathological features are very heterogeneous, and 
also because SSc-associated myopathy often 
includes several distinct entities with different 
pathogenetic mechanisms involved, and with dis-
tinct outcomes [Ranque et  al. 2007; Morrisroe 
et al. 2015]. Even when focusing on muscle histo-
pathological findings only, no clear-cut classifica-
tion has emerged [Paik et  al. 2015]. Therefore, 
novel insights on the immunopathological nature 
of SSc muscle involvement are needed. For this 
reason, in this study we tried to identify histo-
pathological hallmarks that could be specific for 
SSc myopathy and not common to other IIM and 
NIM. Whether the association of IIM and SSc 
constitutes an overlap syndrome or should be 
considered a SSc manifestation still remains 
controversial [Troyanov et  al. 2005; Bhansing 
et  al. 2014]. We demonstrated that fibrosis 
(81%) and microangiopathy (92%) are the main 
Figure 2. Immunohistological distribution (top) of HLA-ABC and MAC. Sarcolemmal and cytoplasmic HLA-
ABC neoexpression is predominant in IIM and SSc groups. Necrotic fibers, identified by deposits of the 
terminal complex of complement, or MAC are particularly common to IIM group, while MAC deposits on 
capillary walls are particularly abundant in SSc group. Bars are set at 100 µm. Quantitative analysis (bottom): 
HLA-ABC is statistically higher in SSc myopathy (**p < 0.01, Kruskal–Wallis) and IIM (**p < 0.01, Kruskal–
Wallis) groups compared with NIM group. MAC is highly upregulated in IIM (**p < 0.01, Kruskal–Wallis) and 
SSc-myopathy (*p < 0.05, Kruskal–Wallis) groups compared with NIM group.
HLA-ABC, human leucocyte antigens ABC; IIM, idiopathic inflammatory myopathies; NIM, noninflammatory myopathies; 
SSc, systemic sclerosis.
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histopathologic hallmarks of SSc-related myopa-
thy. We evidenced a reduced vascularization of 
muscle fibers through the analysis of CD31, and 
the prevalence of anti-angiogenic isoform VEGF-
A165b, as confirmed by other researchers, finding 
increased VEGF-A165b plasmatic levels in SSc 
patients [Manetti et  al. 2013]. However, these 
vascular alterations are not specific to SSc; they 
could be present also in other IIM myopathies, 
such as PM and DM, as has been well described 
in the literature [Volpi et al. 2013]. Regarding the 
inflammatory infiltrate, our study detected an 
absence of inflammatory cells in the majority of 
SSc cases (85%). MAC capillary deposits, com-
patible with a humoral immune process, suggest 
that endothelial injury and intimal proliferation 
may be mediated by complement-fixing anti-
bodies [Evans et al. 1987]. Loss in muscle small 
endomysial vessels in SSc myopathy indicates 
a vasculopathy, with proliferative changes of 
the vessels wall, as evidenced by ultrastructural 
examination, as an early step in tissue damage, in 
analogy with skin and internal organs [Asano and 
Sato, 2015]. Nevertheless, HLA-ABC upregula-
tion is considered an immunohistologic hallmark 
of inflammatory myopathies [Dalakas, 2010]. 
In view of our consistent finding of MHC-I 
fibral staining on SSc myopathy, with no relevant 
infiltrates or myonecrosis, a role of pleiotropic 
TGF-β might be speculated about as a negative 
Figure 3. Immunohistology (top) and relative quantitative analysis (bottom) of CD31 (left), VEGF-A,  
VEGF-A165b (middle) and Coll-I, TGF-β-A (right) in NIM, IIM and SSc groups, respectively. CD31+ vessels 
(arrows) are abundant and surrounding myofibers in NIM group, while they decrease in particular in the 
SSc group. The density of CD31+ endomysial vessels, expressed as capillary to fiber ratio of muscle area, is 
statistically decreased in SSc myopathy group compared with IIM (*p < 0.05, Kruskal–Wallis) and to NIM  
(**p < 0.01, Kruskal–Wallis) groups. VEGF-A and VEGF-A165b seem equally expressed in small endomysial 
vessels of NIM group; in SSc group, VEGF-A shows only the stain of endomysial vessels (arrows), while 
VEGF-A165b also shows a diffuse cytoplasmic stain of myofibers (arrows). The VEGF-A165b:VEGF-A ratio is 
statistically higher in SSc myopathy (**p < 0.01, Kruskal–Wallis) and IIM (*p < 0.05, Kruskal–Wallis) groups 
compared with NIM group. Coll-I and TGF-β are expressed only by some resident endomysial fibroblasts 
(arrows) in NIM group, while they are expressed by both infiltrate cells and activated fibroblasts surrounding 
necrotic fibers in IIM group (arrows). In SSc group, endomysial activated fibroblasts or myofibroblasts are 
strongly reactive to Coll-I and TGF-β (arrows). Quantitative analysis demonstrated that endomysial expression 
of Coll-1 is significantly higher in SSc-myopathy group compared with IIM (*p < 0.05, Kruskal–Wallis) and to 
NIM (**p < 0.01, Kruskal–Wallis) groups. TGF-β is strongly upregulated in SSc myopathy group compared with 
IIM (**p < 0.01, Kruskal–Wallis) and NIM (**p < 0.01, Kruskal–Wallis) groups. Bars are set at 100 µm.
IIM, idiopathic inflammatory myopathies; NIM, noninflammatory myopathies; SSc, systemic sclerosis; TGF-β-A, 
transforming growth factor β-A; VEGF-A, pro-angiogenic vascular endothelial growth factor A; VEGF-A165b, anti-angiogenic 
vascular endothelial growth factor A.
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modulator of cell immunity [Morikawa et  al. 
2016], in reducing the extent of muscle inflam-
mation, at least in the early phases of muscle 
involvement, and acting as a pro-fibrotic factor. 
This hypothesis is based on the documented 
upregulation of TGF-β in scleroderma lesional 
skin, where it induces the activation of myofi-
broblasts [Nikitorowicz-Buniak et  al. 2015]. 
However, it must be remembered that the litera-
ture reported some cases of SSc myopathy with 
inflammatory cells, predominantly CD8+ T lym-
phocytes with lower levels of CD4+ cells, few B 
cells and no complement capillary deposits 
[Bhansing et al. 2014], as well as some cases with 
a majority of CD4+ T cells and B cells and com-
plement deposits [Ranque et al. 2007]. Therefore, 
data related to the inflammatory infiltrate and 
the nature of immune response seem controver-
sial and different possible patterns are envisaged. 
In conclusion, our suggestion is to study and 
characterize each case of muscle involvement in 
SSc from the histological/immunohistological 
point of view, because of the heterogeneity of its 
manifestations. This advice is not simply specu-
lative, but responds to the need to set up the suit-
able therapy for each case. In fact, high-dose 
steroids represent the first line treatment for all 
myositides except IBM [Dalakas, 2010]; in SSc 
myopathic patients, highly susceptible to renal 
crisis, corticosteroids at the lowest effective dose 
should be restricted to subjects with histologi-
cally proven inflammation. Further studies 
should follow to determine whether histopatho-
logic findings in SSc-related myopathy could 
influence clinical outcomes of specific targeted 
therapies.
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